The Carlyle Group is a global investment firm that specializes in various asset classes, including private equity, real estate, and credit. The company connects capital from investors with opportunities across a diverse range of industries and geographies, focusing on generating value through strategic investments and active management. With a strong emphasis on relationships, Carlyle collaborates with portfolio companies to enhance their growth prospects and operational efficiency, ultimately aiming to deliver attractive returns for its investors while maintaining a commitment to responsible investment practices. Read More
CommScope shares are trading higher Monday after Amphenol announced it will acquire the company's Connectivity and Cable Solutions segment for $10.5 billion.
Adastra Group SE (“Adastra”), a leading global IT consultancy and services provider specializing in AI, data and cloud transformations today announced that Global investment firm Carlyle (NASDAQ: CG) has agreed to acquire a majority stake in the Group. Completion of the acquisition is subject to standard regulatory approvals in several jurisdictions.
Proven healthcare marketing leader to drive brand growth and digital engagement in support of the company’s mission to innovate health solutions that accelerate better health outcomes
BIRMINGHAM, Ala. and NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Diversified Energy Company PLC (LSE: DEC; NYSE: DEC) ("Diversified," or "DEC"), a leading publicly traded natural gas and liquids production company, and global investment firm Carlyle (NASDAQ: CG) have today announced a strategic partnership to invest in up to $2 billion in existing proved developed producing (PDP) natural gas and oil assets across the United States.
Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right (“CVR”) if bluebird’s current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027 or (y) $5.00 per share in cash (the “Offer”), expired as scheduled at one minute after 11:59 p.m. New York City time on May 29, 2025 (the “Expiration Time”) and was not extended.
As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated instructions for stockholders to tender their shares into the offer.
